ACRS logo

ACRS
Aclaris Therapeutics Inc

4,953
Mkt Cap
$492.03M
Volume
617,389.00
52W High
$4.89
52W Low
$1.08
PE Ratio
-7.63
ACRS Fundamentals
Price
$4.04
Prev Close
$4.08
Open
$4.08
50D MA
$3.50
Beta
1.16
Avg. Volume
2.75M
EPS (Annual)
-$0.5297
P/B
4.72
Rev/Employee
$107,205.48
$280.28
Loading...
Loading...
News
all
press releases
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Moderate Buy" by Analysts
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat reports...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Wall Street Zen
Wall Street Zen raised Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·7d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 10.2% - What's Next?
Aclaris Therapeutics (NASDAQ:ACRS) Shares Up 10.2% - Time to Buy...
MarketBeat·10d ago
News Placeholder
Aclaris Therapeutics' (ACRS) Outperform Rating Reaffirmed at Wedbush
Wedbush restated an "outperform" rating and issued a $8.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday...
MarketBeat·11d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Shares Pass Below 50 Day Moving Average - Should You Sell?
Aclaris Therapeutics (NASDAQ:ACRS) Stock Crosses Below 50-Day Moving Average - Here's What Happened...
MarketBeat·11d ago
News Placeholder
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·16d ago
News Placeholder
Q1 EPS Estimate for Aclaris Therapeutics Raised by Analyst
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Analysts at HC Wainwright boosted their Q1 2026 EPS estimates for shares of Aclaris Therapeutics in a research note issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earning...
MarketBeat·19d ago
News Placeholder
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a research report on Thursday...
MarketBeat·23d ago
News Placeholder
HC Wainwright Has Positive Forecast for ACRS FY2026 Earnings
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at HC Wainwright increased their FY2026 earnings per share estimates for Aclaris Therapeutics in a research report issued...
MarketBeat·24d ago
News Placeholder
Research Analysts Offer Predictions for ACRS FY2027 Earnings
Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a note...
MarketBeat·25d ago
<
1
2
...
>

Latest ACRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.